Brand-new PxPulse Podcast on LEN's Impact on HIV Prevention 🎧
View this email in your browser ([link removed])
[link removed] September 18, 2024
** Brand-new PxPulse Podcast on LEN's Impact on HIV Prevention
------------------------------------------------------------
Dear Advocate,
The promise of long-acting PrEP has been super-charged this year by studies showing the powerful efficacy of an injectable antiretroviral known as lenacapavir (LEN). ([link removed])
PxPulse’s new episode, Lenacapavir: The case for investing in delivering HIV prevention ([link removed]) , goes deep on LEN. Recorded just days before Gilead’s announcement ([link removed]) that PURPOSE 2 ([link removed]) , its second major trial of LEN as injectable PrEP, also found very high efficacy, Dr. Flavia Kiweewa, a principal investigator of PURPOSE 1 ([link removed]) , the first trial to announce efficacy, lays out the research findings and what they mean. And Chilufya Kasanda Hampongo of Zambia’s Treatment Advocacy and Literacy Campaign and Mitchell Warren of AVAC talk about how to change a long history of squandered opportunities to get rollout right.
[link removed]
The PURPOSE 1 ([link removed]) trial announced findings in June that a twice-yearly injection of LEN was 100% effective among cisgender women, with zero new cases of HIV. And the PURPOSE 2 ([link removed]) trial among cisgender men, and trans and non-binary people, was shown to reduce the risk of HIV by 96%.
LEN now enters a select category, one of five ARV-based options for PrEP that all protect against HIV if you take them. But many of the people applauding the results from PURPOSE 1 and 2 will tell you that breakthrough science like this, as hard as it is, is still the easy part. Breaking the back of the HIV epidemic demands overcoming an altogether different challenge — coordinating and accelerating every step in rolling out new products ([link removed]) so that everyone who needs HIV prevention can get it.
Listen to this podcast ([link removed]) to learn what must be done to finally deliver on the promise of highly effective HIV prevention, from pills to rings to injectable PrEP and beyond.
Best,
AVAC
P.S. We’re talking event-driven PrEP next Tuesday on The Choice Agenda. Join us ([link removed]) ! And stay tuned for details on an upcoming webinar on all things LEN.
Follow us @hivpxresearch ([link removed])
[link removed] [link removed] [link removed]
Share this issue ([link removed]) [link removed]
AVAC Global Advocacy for HIV Prevention
+1 212 796 6423
[email protected] (mailto:
[email protected]) www.avac.org ([link removed])
You're receiving this because you signed up for our newsletter. Not interested any longer?
Manage email preferences ([link removed]) | Unsubscribe ([link removed])
